GDP: good distribution practice

Good distribution practice (GDP) is the quality standard for storing, transporting and trading medicines so their quality holds from factory to pharmacy.

Also known as: good distribution practices, EU GDP guidelines

3 min readUpdated

Reviewed by Gosia Luksza, CEO at Regunaut

At a glance

Legal basis
Articles 80 and 84 of Directive 2001/83/EC
Guidelines
Commission Guidelines of 5 November 2013 (2013/C 343/01)
Applies to
Wholesale distributors, manufacturers that distribute, and brokers in part
Evidence
GDP certificate in EudraGMDP after inspection

How it works

Article 80 of Directive 2001/83/EC obliges holders of a wholesale distribution authorisation to comply with the principles and guidelines of good distribution practice, and Article 84 has the Commission publish them. The current text is the Guidelines of 5 November 2013 on Good Distribution Practice of medicinal products for human use (2013/C 343/01). Separate guidelines of 2015 (2015/C 95/01) cover the distribution of active substances. GDP also applies to manufacturers when they distribute their own products, and one chapter applies to brokers.

The guidelines have ten chapters: quality management; personnel, including the responsible person; premises and equipment; documentation; operations; complaints, returns, suspected falsified medicines and recalls; outsourced activities; self-inspections; transportation; and specific provisions for brokers. In practice they require a quality system with change control, deviation management and risk management; qualification of every supplier and customer, by checking that each holds the right authorisation; temperature mapping of storage areas and monitoring of storage conditions; qualified equipment and validated computerised systems; transport that keeps products within their labelled storage conditions, with deviations reported and assessed; segregation of returned, recalled, rejected and suspected falsified stock; and records that allow every delivery to be traced to its supplier and its customer.

Compliance is checked by inspection. Under Article 111 of Directive 2001/83/EC the authority inspects wholesalers and, within 90 days of an inspection that shows compliance, issues a GDP certificate, which is entered in EudraGMDP together with the wholesale distribution authorisation. A statement of non-compliance is entered if the inspection fails. For a marketing authorisation holder, GDP reaches beyond its own warehouse: storage and transport must keep the product within the conditions in section 6.4 of the SmPC and on the labelling, temperature excursions in transit have to be assessed against the stability data in the dossier, and contracts with logistics providers must set out who is responsible for what. Since the Falsified Medicines Directive, wholesalers also verify the safety features on a risk basis.

What goes wrong

Supplier and customer checks are done at onboarding and never repeated, so a lapsed or suspended authorisation goes unnoticed; temperature mapping was done once, in winter, for a warehouse that has since been rearranged; transport is outsourced without a written agreement or an audit, and excursion data arrive after the product has been delivered; returns go back into saleable stock without evidence of how they were stored; the responsible person is left out of decisions that the guidelines assign to them personally; and excursions are closed by the wholesaler without asking the marketing authorisation holder, who holds the stability data needed to judge them. Inspectors grade deficiencies as critical, major or other, and a critical deficiency can end in a non-compliance statement that customers and suppliers will see in EudraGMDP.

Timing

Within 90 days of an inspection that shows compliance, the authority issues a GDP certificate under Article 111(5) of Directive 2001/83/EC. Reinspection follows on a risk basis. Wholesalers must keep their transaction records for five years.

GDP: common questions

What is the difference between GMP and GDP?

Good manufacturing practice covers how a medicine is made, tested and released, and applies to manufacturers and importers. Good distribution practice covers what happens after release: storage, transport, and buying and selling between authorised companies. Both are enforced by inspection and recorded in EudraGMDP, with GMP certificates for manufacturing sites and GDP certificates for wholesalers.

Who has to comply with GDP?

Every holder of a wholesale distribution authorisation, manufacturers when they distribute their own products, and brokers for the chapter that applies to them. Warehouses that hold medicines need their own authorisation. Transport companies are covered through the wholesaler's written agreements and audits, under the chapter on outsourced activities.

How do I check whether a wholesaler is GDP compliant?

Search EudraGMDP, EMA's public database, for the company's wholesale distribution authorisation and its GDP certificate, and read the scope: the premises, the activities and the product categories covered. The database also lists statements of non-compliance. The GDP guidelines expect suppliers and customers to be qualified before the first transaction and rechecked periodically.

Sources

  1. EUR-Lex: Guidelines of 5 November 2013 on Good Distribution Practice of medicinal products for human use (2013/C 343/01)
  2. European Medicines Agency: Good distribution practice
  3. EUR-Lex: Directive 2001/83/EC on the Community code relating to medicinal products for human use

Put your GDP question to Workbench

Workbench answers regulatory questions from EUR-Lex, EMA, national agencies and your own documents, with every claim linked to its source. Start free with welcome credits.